Smoking Cessation Med May Also Help Cocaine Dependence
Thursday, February 2nd, 2012
The partial agonist varenicline (Chantix, Pfizer), which is commonly used as a smoking cessation treatment, may also be effective in treating cocaine dependence, new research suggests. In a small, randomized study of 37 cocaine-dependent adults, those treated with varenicline experienced significantly lower levels of reward effect from cocaine compared w their counterparts treated with placebo.
Participants receiving varenicline also had lower odds of cocaine use, which was the study’s primary outcome measure, but this finding was not statistically significant.
“Because it’s a small-scale study, it was underpowered. But the fact that we did see these effects with such low power suggests that there might really be something there,” lead author Jennifer G. Plebani, PhD, research assistant professor in the Department of Psychiatry and director of the Human Behavior and Pharmacology Laboratory in the Treatment Research Center at the University of Pennsylvania Perelman School of Medicine in Philadelphia, told Medscape Medical News.
Dr. Plebani noted that there are currently no established, proven medications for treating cocaine dependence.
“We have medications for treating opiate or alcohol dependence but nothing for this condition. So we’re cautiously optimistic. Anytime we have an additional tool that might help some patients, it’s worth considering” she said.
“I would tell clinicians that if they have someone who is cocaine dependent, and they are not responding to the treatment options that are currently available, it might be worth thinking about using varenicline. And I would recommend using it in combination with psychotherapy.”
The study is published in the February issue of Drug and Alcohol Dependence.
Cardiovascular, Neuropsychiatric Concerns
A recent meta-analysis published in the Canadian Medical Association Journal in July 2011 and reported at the time by heartwire, a sister publication of Medscape Medical News, raised concerns about varenicline and cardiovascular risk.
Researchers from Wake Forest Baptist Medical Center in Winston-Salem, North Carolina. told heartwire at the time that the results highlighted “how dangerous this drug is” and that it only offers “a very modest benefit.”
On the other hand, another investigator who has conducted research with the medication, Taylor Hays, MD, from the Mayo Clinic, wrote in an accompanying editorial that “the small absolute risk of cardiovascular events associated with varenicline treatment is outweighed by the enormous benefit for reducing cardiovascular morbidity and mortality that can be achieved with successful smoking abstinence.”
In addition, a study published in PLoS One in November 2011, investigators from Wake Forest also reported that varenicline was associated with a significantly increased risk for suicidal behavior and depression compared with other smoking cessation medications.
This was in marked contrast to a review by the US Food and Drug Administration (FDA) published the month before that examined 2 epidemiological studies that showed no differences in risk for neuropsychiatric adverse events between varenicline and nicotine replacement therapy.
However, the FDA also reported that these studies had a number of limitations and that clinicians should continue following the recommendations listed on the physician label and in the patient medication guide — and to carefully monitor use.
Nevertheless, “based on FDA’s assessment of currently available data, the Agency continues to believe that the drug’s benefits outweigh the risks and the current warnings in the Chantix drug label are appropriate,” the organization noted in a release at the time.








